Selectively inhibiting PKM2 starves cancer cells

January 23, 2012

Crippling a protein that allows cancer cells to grow when oxygen is scarce causes tumors to regress, according to a study published online on January 23 in the Journal of Experimental Medicine.

An enzyme called PKM2 (M2 isoform of pyruvate ) is ramped up in cancer cells, allowing them to generate energy in the harsh, low-oxygen environment found within tumors.

Michael Goldberg and Phillip Sharp at the Massachusetts Institute of Technology now find that inhibiting PKM2 kills by starving them of energy but leaves normal cells unscathed. Crippling PKM2 caused established tumors in mice to melt away. If these results hold true in humans, this strategy could prove effective against a wide spectrum of cancers with minimal side effects.

Explore further: Study identifies an expanded role for PKM2 in helping cancer cells survive

More information: Goldberg, M.S., and P.A. Sharp. 2012. J. Exp. Med. doi:10.1084/jem.20111487

Related Stories

Recommended for you

Targeting fat to treat cancer

September 19, 2016

Fat isn't just something we eat: it may also lie at the heart of a new approach to treating cancer.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.